Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by MiningMonsteron Nov 21, 2010 6:02pm

593 Views

Post# 17736564

RE: Ok for the short term

Nice analysis, the buyers have definately been gathering momentum over the last few days, quite the fury of activity and many millions placed in fresh, strong hands.

The 50% retracement line is at approx $4.40, they will likely pay up to around these levels over the next couple of days until these allotments are filled

Cheers

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity